Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer.
Nataliya MarArash Rezazadeh KalebastyPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Use of adjuvant checkpoint inhibitors in patients post neoadjuvant cisplatin-based chemotherapy with pathologic advanced disease at the time of radical cystectomy at high-risk of cancer recurrence sounds appealing. Careful patient selection based on tumor-specific genomic alterations may be key. Large trials addressing this question are ongoing.
Keyphrases
- locally advanced
- end stage renal disease
- muscle invasive bladder cancer
- early stage
- rectal cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- lymph node
- neoadjuvant chemotherapy
- dna damage
- peritoneal dialysis
- case report
- squamous cell carcinoma
- radiation therapy
- cell cycle
- papillary thyroid
- dna methylation
- cell proliferation
- young adults
- genome wide
- free survival
- patient reported